NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.97 -0.03 (-0.60 %) (As of 05/26/2020 02:24 PM ET) Add Compare Share Today's Range$4.93Now: $4.97▼$5.1650-Day Range$3.79MA: $4.43▼$5.0852-Week Range$2.85Now: $4.97▼$7.21Volume34,679 shsAverage Volume986,937 shsMarket Capitalization$496.50 millionP/E RatioN/ADividend YieldN/ABeta0.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingBioDelivery Sciences International has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.71, BioDelivery Sciences International has a potential upside of 75.2% from its current price of $4.97.Amount of Analyst CoverageBioDelivery Sciences International has only been the subject of 4 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesBioDelivery Sciences International has received 535 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioDelivery Sciences International has received 339 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioDelivery Sciences International has received 61.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote “Outperform” if you believe BDSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioDelivery Sciences International does not currently pay a dividend.Dividend GrowthBioDelivery Sciences International does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioDelivery Sciences International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,561,729.00 in company stock.Percentage Held by InsidersOnly 8.94% of the stock of BioDelivery Sciences International is held by insiders.Percentage Held by Institutions73.64% of the stock of BioDelivery Sciences International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioDelivery Sciences International are expected to grow by 131.58% in the coming year, from $0.19 to $0.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioDelivery Sciences International is -55.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioDelivery Sciences International is -55.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioDelivery Sciences International has a P/B Ratio of 6.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.88 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:BDSI Previous Symbol CUSIP09060J10 CIK1103021 Webwww.bdsi.com Phone919-582-9050Debt Debt-to-Equity Ratio0.77 Current Ratio2.19 Quick Ratio1.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio26.16 P/E GrowthN/A Sales & Book Value Annual Sales$111.39 million Price / Sales4.46 Cash Flow$0.19 per share Price / Cash Flow26.67 Book Value$0.78 per share Price / Book6.37Profitability EPS (Most Recent Fiscal Year)$0.10 Net Income$-15,310,000.00 Net Margins-5.01% Return on Equity23.61% Return on Assets9.21%Miscellaneous Employees178 Outstanding Shares99,900,000Market Cap$496.50 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:BDSI Rates by TradingView Receive BDSI News and Ratings via Email Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter. BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions How has BioDelivery Sciences International's stock been impacted by COVID-19 (Coronavirus)? BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BDSI stock has increased by 25.5% and is now trading at $4.97. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International. When is BioDelivery Sciences International's next earnings date? BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International. How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company had revenue of $38.28 million for the quarter, compared to analysts' expectations of $33.19 million. BioDelivery Sciences International had a negative net margin of 5.01% and a positive return on equity of 23.61%. View BioDelivery Sciences International's earnings history. What price target have analysts set for BDSI? 8 brokers have issued 1 year price objectives for BioDelivery Sciences International's shares. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's stock price to reach $8.71 in the next year. This suggests a possible upside of 75.2% from the stock's current price. View analysts' price targets for BioDelivery Sciences International. Has BioDelivery Sciences International been receiving favorable news coverage? News stories about BDSI stock have trended negative on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutBioDelivery Sciences International. Who are some of BioDelivery Sciences International's key competitors? Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD). Who are BioDelivery Sciences International's key executives? BioDelivery Sciences International's management team includes the following people: Mr. Herm Cukier, CEO & Director (Age 54, Pay $599.46k)Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 55, Pay $410.71k)Ms. Mary Theresa Coelho, CFO & Treasurer (Age 58, Pay $410.7k)Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $340.28k)Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 59, Pay $377.89k) What is BioDelivery Sciences International's stock symbol? BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI." Who are BioDelivery Sciences International's major shareholders? BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.43%), Systematic Financial Management LP (2.39%), Emerald Advisers LLC (2.18%), State Street Corp (1.92%), Emerald Mutual Fund Advisers Trust (1.98%) and Nuveen Asset Management LLC (1.71%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International. Which institutional investors are selling BioDelivery Sciences International stock? BDSI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Assenagon Asset Management S.A., BlackRock Inc., Bank of New York Mellon Corp, WINTON GROUP Ltd, and Squarepoint Ops LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International. Which institutional investors are buying BioDelivery Sciences International stock? BDSI stock was bought by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Stonepine Capital Management LLC, AQR Capital Management LLC, Systematic Financial Management LP, Grandeur Peak Global Advisors LLC, DG Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., and Cadence Capital Management LLC. View insider buying and selling activity for BioDelivery Sciences International. How do I buy shares of BioDelivery Sciences International? Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioDelivery Sciences International's stock price today? One share of BDSI stock can currently be purchased for approximately $4.97. How big of a company is BioDelivery Sciences International? BioDelivery Sciences International has a market capitalization of $496.50 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe. What is BioDelivery Sciences International's official website? The official website for BioDelivery Sciences International is www.bdsi.com. How can I contact BioDelivery Sciences International? BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
